Merck KGaA Agrees to Acquire Silence Therapeutics for $20.00 Per ADS in $1.3 Billion Deal

Merck KGaA has agreed to acquire Silence Therapeutics in an all-cash transaction that values the company at roughly $1.3 billion in equity, with Silence shareholders set to receive $20.00 per American Depositary Share, according to reporting from Seeking Alpha and StockTitan. The agreement was announced on October 19, 2026, as part of a broader day of dealmaking across sectors.

What Was Announced

Under the terms described by Seeking Alpha, Merck KGaA, which trades as MKGAY and MKGAF, has agreed to buy Silence Therapeutics, which trades under the ticker SLN, in an all-cash deal. Seeking Alpha reported the transaction carries an enterprise value of $1.1 billion against an equity value of approximately $1.3 billion. StockTitan likewise reported the deal was struck "for $20.00 per ADS (~$1.3 billion equity value)" and dated the announcement to October 19, 2026.

The gap between the reported enterprise value of $1.1 billion and the reported equity value of roughly $1.3 billion implies a difference of about $0.2 billion. By our calculation ($1.3B equity value minus $1.1B enterprise value = approximately $0.2B), that spread is typically attributable to a target's net cash position, though neither source detailed Silence's balance sheet directly, so this figure should be read as an inference from the two reported totals rather than a disclosed cash balance.

A Busy Day for Announced Transactions

The Silence agreement was not an isolated headline. StockTitan's roundup of October 19, 2026 market news also flagged MKS's agreement to sell its Ophir Optics business to TTM Technologies for $650 million in cash, a transaction the outlet noted was "subject to customary closing adjustments and excluding Ophir Instruments and the Ophir brand." That deal is unrelated to the Merck KGaA-Silence transaction but appeared in the same day's dealmaking coverage.

What the Reporting Does Not Establish

The available reporting states the headline price, the equity and enterprise value figures, and the announcement date, but it does not specify a closing timeline, required regulatory approvals, break fees, or any go-shop provisions tied to the agreement. Nor does it detail which Silence pipeline programs, if any, factored into Merck KGaA's decision, or how the German company intends to fund the purchase. Readers should treat those as open questions until the companies or their respective filings disclose further terms; this article does not speculate on figures or rationale beyond what Seeking Alpha and StockTitan have reported.

Reading the Numbers

From a purely descriptive standpoint, a $20.00 per-ADS cash offer removes the element of exchange-ratio risk that accompanies stock-for-stock mergers, since Silence holders would receive a fixed dollar amount rather than shares of the acquirer. That said, the sources reviewed here do not state where Silence shares were trading immediately before the announcement, so it is not possible to calculate a verified premium to the prior close or to any trailing average without inventing a reference price. Any premium figure circulating elsewhere should be checked against primary disclosures rather than assumed from the deal price alone.

Bottom Line

Merck KGaA's agreement to acquire Silence Therapeutics for $20.00 per ADS, valuing the company at about $1.3 billion in equity and $1.1 billion on an enterprise basis, was reported by Seeking Alpha and StockTitan on October 19, 2026. Investors looking for deal mechanics such as the expected closing timeline, financing structure, or the treatment of any existing Silence collaborations will need to watch for additional company disclosures, as the current reporting does not address those specifics.